Your SlideShare is downloading. ×
Challenges to indian bt industry
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Challenges to indian bt industry

1,424
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,424
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
38
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. CHALLENGES TO INDIAN
    BIOTECHNOLOGICAL RESEARCH
    AND
    INDUSTRIES.
    AJINDER AND SWATI
    8013 ,8011
    MSC.BIOTECHNOLOGY
  • 2. Contents
    Biotechnology and India
    Indian market
    SWOT analysis
    Challenges faced
    Biotech business in India
    Ipr &biotech industry
    Future of Indian biotech sector
  • 3. BIOTECHNOLOGY AND INDIA
    Quite nascent stage.
    Biodiversity of India is an advantage for biotech sector.
    Over 300 registered biotech companies, out of which 100 are in modern biotech sector.
    12th most successful biotech sector in world,
    3rd largest in Asia with 96 enterprises(after Australia and china).
  • 4. INDIAN BIOTECH MARKET
    Total biotech sectors: $420 million in 2002-03.
    Vaccines : bharat biotech, shanta biotech,pfizer, panacea,etc.
    Therapeutics : biocon, eli lily, etc.
    Diagnostics : span diagnostics,j.mitra, xcyton
  • 5.
  • 6.
  • 7. SWOT ANALYSIS
    Strength, weakness , opportunity, threats,
    Best way to make critical analysis of scientific research in country.
  • 8. STRENGTH:
    Human Resource: Trained manpower and knowledge base.
    •Academic Resource: Good network of research laboratories.
    •Industry Base: Well developed base industries (e.g. pharmaceuticals, seeds).
    •International Experts: Access to intellectual resources of NRI’s in this area.
    •Clinical Capability: Extensive clinical trials and research access to vast and diverse disease in the huge population.
    •Bio-diversity: India’s human gene pools and unique plant, animal & microbial diversity offer an exciting opportunity for genomic research.
    •Stem Cells Research: Several labs have commenced research in stem cells and have valuable stem cell lines.
  • 9. Weakness
    Indian Biotechnology: Weakness
    Missing link between research and commercialization
    •Lack of venture capital
    •Relatively low R&D expenditure by industry
    •Image of Indian industry –doubts about ability of Indian products to meet International standards of quality
  • 10. Opportunities
    indian Biotechnology: Opportunities
    •Large domestic market
    •Large export potential
    •Low cost research base for international companies in comparison with other countries
    •Vast and diverse disease based patient populations provide unique opportunities for clinical research and clinical trials
    •Supportive Government policy on embryonic stem cells research provides a useful opportunity for International companies to pursue such research in India
    •Human bio-diversity provides unique research opportunity in genomics
    •Plant & microbial bio-diversity provides vast prospecting opportunities for new drugs
    •Conducive Government policy on GM crops provides useful opportunities for Agri-biotech companies
  • 11. Threats
    Exodus of brilliant brain to other countries.
    Enhanced level of politics in system.
    Improper utilization of enormous funds.
    Lack of scientific responsibility among young scientist.
  • 12. Challenges faced by indian biotechnological sector
    Weak entrepreneurial skills
    Lack of quality human resource
    Lack of public private partnership.
    Risk averse nature of industry.
    Lack of venture funding
  • 13. Lack of ignition grant system.
    Streamlining the regulatory process.
    Time to market.
    Poor feasibility of indian market.
    Partnership with pharmaceutical industry.
  • 14. Business in india
    Joint venture
    Collaborative research.
    Contract research
    Technology transfer
    Clinical research.
  • 15. IPR and the Biotech Industry
    Ipr importance
    •IP is a central issue in any industry
    •Robust intellectual property rights framework is the need of the hour
    •India is already member of
    –Paris Convention
    –PCT
    –Berne Convention
    –Convention on biological diversity
    –WTO
    •Should make legislation clear on the criteria for the patentability of biotechnological inventions
  • 16. Ipr scenario in India(challenges):
    need to improve patent legislation
    infrastructure needs attention
    till 2005 only process were granted patent.
    poor patent protection & litigation attracts
    less foreign ventures.
    inefficient indian judicial system.
  • 17. What can be Claimed?
    –Diagnostic tests
    –Research tools
    –Gene therapy
    –Therapeutic proteins Sensors
    –Bioinformatics
    –Sequences
    –Pharmaceuticals
  • 18. The future of Biotechnology
    •Developing diverse, collaborative relationships to strengthen its industry
    •Harmonizing standards with international standards in manufacturing and laboratory practices (ensuring foreign markets and enhancement of the industry’s global and local standing)
    •Cheaper labor, technical capacity and expertise may capture markets away from companies in the developed countries
    •Illustrates the importance of fostering a regulatory and IP environment (encouraging innovative startup companies)
  • 19. THANK YOU!!!!